Applied Statistics
Pharmacology 2013
Queen Elizabeth II Conference Centre
Broad Sanctuary
Westminster London, UK
Pharmacology 2013 
Queen Elizabeth II Conference Centre
Broad Sanctuary
Westminster London

Schedule of Presentations:

Tuesday, December 17, 2013
06:00:00 New Presentation
06:00:00 New Presentation
10:00:00 If Nothing Happens, Is Everything Alright? – a guide to making sense of conflicting data
10:00:00 New insights into 5-HT6 receptors signalling and pathophysiology
10:00:00 Introduction Domenico Spina
10:00:00 Introduction Steve Rannard
10:05:00 The application of nanotechnologies, priorities for industry
10:05:00 ASPA after 2013 – how are we doing?
10:35:00 UK academic community perspectives Domenico Spina
10:40:00 Synthesis of safe, effective and scalable polymers to enable nanomedicines
10:40:00 Targeting of pre- and post-synaptic 5-HT1A receptor sub-populations by selective biased agonists
10:45:00 Toxicology cases
10:55:00 Discussion
11:15:00 Coffee Break
11:15:00 Coffee break
11:30:00 Coffee break
11:45:00 Iterating synthesis with pharmacology to accelerate nanomedicine development Andrew Owen
11:45:00 Pharmacoepidemiology and pharmacoeconomics – principles and practice
11:45:00 Industry perspectives of 2013
11:45:00 Tickling the 5-HT3 receptor for therapeutic benefit; opportunities from allosteric modulation of the 5-HT3 receptor
12:05:00 Across the Channel: European view of the Directive
12:20:00 Tools for early evaluation of nanomedicine safety
12:25:00 What does openness mean in animal research?
12:25:00 5-HT receptor adaptor proteins Per Svenningsson
12:45:00 Discussion
13:00:00 Lunch break
13:30:00 GSK Prize Lecture: A 'green' approach to cardiovascular disease: recycling inorganic nitrate and nitrite
14:45:00 StR training session assessment Peter Jackson
23:15:00 Coffee break
Wednesday, December 18, 2013
06:00:00 New Presentation
06:00:00 New Presentation
06:00:00 New Presentation
09:00:00 From proteomics to prescription: the search for biomarkers of asthma and COPD
09:00:00 Overview on the inflammasome Eicke Latz
09:00:00 Introduction and summary of recent changes in the UK management of paracetamol poisoning
09:20:00 Epidemiology of paracetamol poisoning in the UK and the impact of pack-size legislation
09:20:00 The non-canonical Inflammasome Pathway Vishva Dixit
09:30:00 Genomic studies in angiogenesis and inflammation: A pioneering discovery of a novel drug target
09:50:00 Metabolomic Perspectives on Acetaminophen Toxicity
10:00:00 Selected abstract from the Younger Members Section
10:15:00 Coffee break
10:15:00 Coffee break
10:20:00 Coffee break
10:45:00 Role of the NALP3 inflammasome in infectious diseases
10:45:00 The Promise and Limitations of Gene Expression Analysis in Cardiovascular research
10:50:00 Novel biomarkers – current and future application to the management of paracetamol poisoning
11:15:00 Keynote presentation: The birth of metabonomics technology and novel approaches to screening drug toxicity Ian Wilson
11:20:00 Pro-Con debate: Was the UK decision to have a lower paracetamol ‘treatment line’ correct?
11:40:00 The role of NALP3 inflammasome in disease: ATP-P2X7 axis is the pathogenesis of smoking related lung inflammation
Thursday, December 19, 2013
06:00:00 New Presentation
06:00:00 New Presentation
06:00:00 New Presentation
09:30:00 Introduction Donald Singer
09:30:00 Novel biomarkers and mechanisms in impulsivity and addiction Jeffrey W Dalley
09:30:00 Clinical Pharmacology of the Hedgehog Pathway Inhibitor Vismodegib: A Prickly Pharmacokinetic Challenge
09:40:00 Microcirculation pharmacology and therapeutic targets Chris Garland
10:05:00 Ascending peptidergic systems regulate reward-seeking: relevance to relapse Andrew John Lawrence
10:10:00 Leukocyte trafficking through microvessels: Emergence of novel anti-inflammatory therapeutic avenues Sussan Nourshargh
10:15:00 Evolutions in therapies for depression
10:45:00 Coffee break
10:45:00 Coffee break
10:45:00 Coffee break
11:15:00 New approaches for modulating retinal angiogenesis
11:15:00 Ticagrelor; an oral purinergic P2Y12 antagonist for the treatment of acute coronary syndromes
11:15:00 Novel neuropharmacological strategies for anxiety and depression
11:40:00 Pharmacological approaches for reducing risk of microvascular stroke syndromes Donald Singer
11:45:00 Abiraterone; a selective, oral CYP17 inhibitor for the treatment of metastatic, castration resistant prostate cancer Gerhardt Attard
11:50:00 Evaluation of novel drugs to treat negative and cognitive deficits of schizophrenia in rats reared in social isolation from weaning Kevin Fone
12:05:00 Therapeutic targeting of angiogenic TGF-beta signaling in the tumor microenvironment Kristian Pietras
12:15:00 Drug Discovery of the Year 2014: announcement of the next phase
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.